Antacid / PPI

Research records

Historical source snapshot. Not freshly verified, not a recommendation. Study findings, community accounts and app defaults are not interchangeable.

Publication suitability · 2026-10-15: Historical reference only; not a clinical verification. Clinical, regulatory, efficacy, safety and dose claims are not independently established by this review.

Antacid / PPI

Omeprazole and similar. Relevant beyond the symptom: sustained acid suppression reduces absorption of magnesium, B12 and iron.

Evidence category: Reference only. This describes the source category, not approval or certainty.

Regulatory statement in source: Not separately recorded; do not infer approval from the evidence category.

Proton pump inhibitors block the H+/K+-ATPase pump in stomach parietal cells and so reduce acid. A 2025 review describes them as widely prescribed for reflux, peptic ulcer disease and prevention of gastrointestinal bleeding. The same review lists interactions, including omeprazole reducing the effect of clopidogrel, and links long-term use to vitamin B12 and calcium deficiency, fractures and more infections. This is a general review, not a regulator label or a trial.

Benefits reported in the imported source

• A 2025 review describes these drugs as widely prescribed for reflux and peptic ulcer disease.
• They block the stomach's acid pump directly, and are used to prevent gastrointestinal bleeding.

Risks and limits

• Long-term use is linked to vitamin B12 and calcium deficiency, fractures and more infections.
• Omeprazole reduces the effect of clopidogrel.
• The single source is a general review, not a regulator label or a trial.

Source bottom line: Proton pump inhibitors cut stomach acid; long-term use is linked to nutrient deficiency, fractures and infections.

Uncertainty: Reference information only. Not medical advice.

Study protocols — reports, not instructions

No study protocol recorded in this snapshot. This does not establish that no study exists.

Community and practice descriptions

Accounts of a practice are not evidence of safety or effectiveness. Words such as “standard”, “safe” or “recommended” describe the source account, not verified consensus or this wiki’s advice. Commercial and self-published citations are retained for traceability, not vendor endorsement or independent clinical corroboration.

Pharmacokinetic context

Historical half-life estimate: 1 hours. FDA label, omeprazole; effect outlasts plasma level Population/route context and estimates may differ. This is not a schedule or a verified human dosing rule.

Source references

• Pharmacodynamics, pharmacokinetics, interactions with other drugs, toxicity and clinical effectiveness of proton pump inhibitors
• DailyMed: omeprazole